Evidence map›Paper›PMID 24920962›Full record

ArticleDiabetology & metabolic syndrome2014

Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats.

Erik Salum, Mark Butlin, Jaak Kals, Mihkel Zilmer, Jaan Eha, Alberto P Avolio, Andres Arend, Marina Aunapuu, Priit Kampus

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Blockade of angiotensin ATBritish journal of pharmacology · 2020
    Article
  3. Article
  4. Cinnamaldehyde exerts vasculoprotective effects in hypercholestrolemic rabbits.Naunyn-Schmiedeberg's archives of pharmacology · 2018
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Erik SalumDepartment of Cardiology, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Endothelial Centre, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Department of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia.
Mark ButlinThe Australian School of Advanced Medicine, 2 Technology Place, Macquarie University, Sydney, NSW 2109, Australia.
Jaak KalsEndothelial Centre, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Department of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia ; Department of Vascular Surgery, Tartu University Hospital, 8 Puusepa Street, Tartu 51014, Estonia.
Mihkel ZilmerEndothelial Centre, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Department of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia.
Jaan EhaDepartment of Cardiology, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Endothelial Centre, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia.
Alberto P AvolioThe Australian School of Advanced Medicine, 2 Technology Place, Macquarie University, Sydney, NSW 2109, Australia.
Andres ArendDepartment of Anatomy, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia.
Marina AunapuuDepartment of Anatomy, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia ; Institute of Veterinary Medicine and Animal Sciences, Estonian University of Life Sciences, 62 Fr. Kreutzwaldi Street, Tartu 51014, Estonia.
Priit KampusDepartment of Cardiology, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Endothelial Centre, University of Tartu, 8 Puusepa Street, Tartu 51014, Estonia ; Department of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, 19 Ravila Street, Tartu 50411, Estonia.
University of Tartu · EEMacquarie University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevention or attenuation of diabetic vascular complications includes anti-hypertensive treatment with renin-angiotensin system inhibitors on account of their protective effects beyond blood pressure reduction. The present study aimed to investigate the effects of telmisartan, an angiotensin II type 1 receptor blocker (ARB), on blood pressure, aortic stiffening, and aortic remodelling in experimental type 1 diabetes in rats.

methodsDiabetes was induced by streptozotocin (STZ) (65 mg/kg) in male Wistar rats. One diabetic group was treated for 10 weeks with telmisartan (10 mg/kg/day p/o). Pressure-independent aortic pulse wave velocity (PWV) was measured under anaesthesia after intravenous infusion of phenylephrine and nitroglycerine. Aortic wall samples were collected for histomorphometrical analysis.

resultsUntreated diabetes imposed differential effects on aortic stiffening, as demonstrated by increased isobaric PWV over a range of high blood pressures, but not at lower blood pressures. This was associated with loss and disruption of elastin fibres and an increase in collagen fibres in the aortic media. Treatment with telmisartan decreased resting blood pressure, reduced aortic stiffness, and partially prevented the degradation of elastin network within the aortic wall.

conclusionsTelmisartan improved the structural and functional indices of aortic stiffening induced by untreated STZ-diabetes, demonstrating the importance of ARBs in the therapeutic approach to diabetic vascular complications.

Indexed as

Arterial stiffnessCollagenDiabetesElastinPulse wave velocityStreptozotocinTelmisartan

Identifiers

PMID24920962
PMCPMC4035834
OpenAlexW2161902506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.